Biotech Paper

Biotech Paper - Christie Strawser Biotechnology Date Due:...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Christie Strawser Date Due: 6/10/2008 Biotechnology Date Submitted: 6/10/2008 When the biotech industry was first starting out, its mission was to create replacements for drugs that were too expensive to produce, too hard to get, or had become too dangerous due to natural contamination. Today the mission is different. Biotech medicine is targeting diseases for which there are no known treatments or preventatives. For vaccines that are already used by the general public, biotech will make them safer, easier and more effective. Seeing as how Biotech is more focused on finding cures than treating diseases, many clinical trials are in progress. “There are now people who have actually been cured of diabetes through biotechnology in clinical trials (9).” Biopharmaceuticals are defined in the book as drugs made from proteins and other organic substances. They are the fastest-growing segment of the entire drug industry (10). “It has increased from less than one percent of the US market in 1989 to seven percent in 1998, according to Gillian Woollett, formerly with the Pharmaceutical Research and Manufacturers of America and now vice president of science and regulatory affairs at the Biotechnology Industry Organization. About one third of approximately one thousand drugs now being tested in patient trials are biopharmaceuticals (10).” In 2002, 234 biotechnology drugs and uses for a drug had been approved in the United States alone. A record number of drugs, 35, were approved that same year. Among these drugs was an interesting and exciting range of applications, “from advanced prostate cancer and torn rotator cuffs to a single vaccine that protects against diptheria, tetanus, pertussis, hepatitis B, and polio (10).” All together theses drugs have helped over 325 million patients worldwide, says BIO, and industry umbrella group. Of the total number of medicines approved in the U.S. in the 1990’s 13% were biopharmaceuticals, according to Nature Biotechnology (10). However, since the establishment of the European Medical Evaluation Agency in 1995, 34 percent of its approved drugs were biotech-based.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
The author points out that definitions of biopharmaceutical may vary. However, genes are the connecting factor. Genes instruct the cells to produce protein. These proteins are often enzymes, which always consist of twenty-two different amino acids. Genes are what direct the biological development and activity of the human body’s estimated one trillion cells. “The difference between these cells is not a result of the particular genes they carry, but whether or not they are switched on or off (11).” Some traits are predestined and some are predisposed. The shape of your lips are predestined, the age at which you might contract a particular disease results from predispositions combined with outside factors. Whether it’s predestiny, or predisposition, it’s uncommon that one gene causes only one outcome. “In a sense, biotech is all about observing
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/04/2009 for the course MKTG 101 taught by Professor Dr.jones during the Spring '09 term at Lindenwood.

Page1 / 11

Biotech Paper - Christie Strawser Biotechnology Date Due:...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online